For me, you can’t have 4 phase 2 assets that are fully funded to complete trials with significant news due in 12 months and be below $40Mn market cap. The CEO issue is not yet a deal breaker for me although he is paid too high ($700k) for a microcap. But when we become a mid cap and his pay stays the same, then it would be about right.
At 10X from here we would still be a small cap, so there is plenty of growth in this story.
AIMO. DYOR.
Add to My Watchlist
What is My Watchlist?
